IRIS - Res&Arch Institutional Research Information System - Research & Archive

BAGLIVO, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 993
AS - Asia 799
EU - Europa 571
SA - Sud America 163
Continente sconosciuto - Info sul continente non disponibili 85
AF - Africa 29
OC - Oceania 2
Totale 2.642
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 956
SG - Singapore 382
CN - Cina 129
BR - Brasile 125
IT - Italia 113
IE - Irlanda 109
HK - Hong Kong 87
RU - Federazione Russa 78
DE - Germania 77
VN - Vietnam 58
FR - Francia 47
RO - Romania 27
BD - Bangladesh 26
KR - Corea 26
FI - Finlandia 24
IN - India 23
GB - Regno Unito 20
AR - Argentina 17
CA - Canada 16
JP - Giappone 13
ES - Italia 12
MX - Messico 12
PL - Polonia 12
AT - Austria 11
MA - Marocco 10
SE - Svezia 10
IQ - Iraq 9
NL - Olanda 8
TR - Turchia 7
ZA - Sudafrica 7
PK - Pakistan 6
VE - Venezuela 6
CH - Svizzera 5
JO - Giordania 5
EC - Ecuador 4
EG - Egitto 4
PY - Paraguay 4
SA - Arabia Saudita 4
TT - Trinidad e Tobago 4
UZ - Uzbekistan 4
GR - Grecia 3
PH - Filippine 3
UA - Ucraina 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BO - Bolivia 2
CO - Colombia 2
DZ - Algeria 2
ID - Indonesia 2
JM - Giamaica 2
LB - Libano 2
LT - Lituania 2
OM - Oman 2
SC - Seychelles 2
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
CL - Cile 1
DO - Repubblica Dominicana 1
GA - Gabon 1
HN - Honduras 1
HU - Ungheria 1
IR - Iran 1
KI - Kiribati 1
LV - Lettonia 1
ME - Montenegro 1
MN - Mongolia 1
MT - Malta 1
MY - Malesia 1
NG - Nigeria 1
NP - Nepal 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
PW - Palau 1
RS - Serbia 1
SI - Slovenia 1
SO - Somalia 1
SV - El Salvador 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
Totale 2.557
Salva come PNG Salva come JPEG
Città #
Singapore 293
Chandler 145
San Jose 121
Dublin 109
Hong Kong 86
Ashburn 67
Santa Clara 39
Beijing 38
San Mateo 35
Boardman 34
Munich 33
Perugia 32
Bucharest 27
Los Angeles 27
Seoul 26
Moscow 25
Lauterbourg 22
Altamura 21
Lawrence 20
Medford 20
New York 20
Princeton 20
Ho Chi Minh City 19
Ann Arbor 14
Frankfurt am Main 14
Helsinki 14
Tokyo 13
Warsaw 12
Andover 11
Piscataway 11
São Paulo 11
Wilmington 11
Chicago 9
Des Moines 9
Hanoi 9
Falkenstein 8
Mexico City 8
Nuremberg 8
Stockholm 8
The Dalles 8
Orem 7
Atlanta 6
Baghdad 6
Hefei 6
San Paolo di Civitate 6
Seattle 6
Brasília 5
Brooklyn 5
Chennai 5
Haiphong 5
Houston 5
Johannesburg 5
Montreal 5
Phoenix 5
Redmond 5
Rio de Janeiro 5
Rome 5
Turku 5
Vienna 5
Amman 4
Arezzo 4
Curitiba 4
Dallas 4
Dearborn 4
Denver 4
Guangzhou 4
Lahore 4
Nanjing 4
Paris 4
Saint Petersburg 4
San Francisco 4
Toronto 4
Amsterdam 3
Ankara 3
Bexley 3
Calgary 3
Council Bluffs 3
Formia 3
Hải Dương 3
Milan 3
Mumbai 3
Poplar 3
Port of Spain 3
Rabat 3
Tianjin 3
Anápolis 2
Bolzano 2
Boston 2
Cairo 2
Caracas 2
City of London 2
Columbus 2
Erbil 2
Faenza 2
Foligno 2
Ghaziabad 2
Governador Valadares 2
Guayaquil 2
LaFayette 2
Lappeenranta 2
Totale 1.680
Salva come PNG Salva come JPEG
Nome #
Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer 128
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib 120
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence 119
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 112
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 108
Non-coding RNAs in lung cancer 105
Osimertinib 101
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 101
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy 97
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 97
Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study 96
KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer 94
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 93
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 90
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 84
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 84
Dynamic network topologies analysis in proteomics data of NSCLC cell lines using a new pipeline based on machine learning tools 84
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 83
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases 82
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 78
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 77
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer 74
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6) 73
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence 73
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. 72
Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs 70
Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations 69
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature 63
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review 56
Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression 52
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review 4
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review 2
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review 1
Totale 2.642
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.364
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.364
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022169 0 25 1 5 4 3 1 47 2 22 24 35
2022/2023398 22 75 9 37 38 40 0 18 142 0 14 3
2023/2024158 8 10 16 6 2 2 39 1 4 5 36 29
2024/2025418 10 31 31 12 46 33 9 32 70 34 67 43
2025/20261.254 65 97 72 185 198 93 189 69 118 115 36 17
2026/202767 32 35 0 0 0 0 0 0 0 0 0 0
Totale 2.642